Covaxin has finally got the long awaited verdict from medical journal The Lancet that found that Bharat Biotech developed vaccine has a 77.8% efficacy rate against symptomatic Covid. Covaxin, which uses traditional, inactivated-virus technology, “induces a robust antibody response” two weeks after two doses are given, The Lancet said in a statement. No severe-vaccine-related deaths or adverse events […]
\
\
